These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 5073303)

  • 1. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern.
    Goldie JH; Price LA; Harrap KR
    Eur J Cancer (1965); 1972 Aug; 8(4):409-14. PubMed ID: 5073303
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacologic studies of methotrexate in cancer patients with uropathy.
    Ojima Y; Anderson LL; Collins GJ; Oberfield RA; Sullivan RD
    Arch Surg; 1970 Feb; 100(2):173-7. PubMed ID: 5411410
    [No Abstract]   [Full Text] [Related]  

  • 3. Methotrexate excretion patterns and renal toxicity after intravenous injection or arterial infusion.
    Patel DD; Morgenthaler FR; Khazei AM; Grimaldi R; Watkins E
    Arch Surg; 1969 Mar; 98(3):305-8. PubMed ID: 4885683
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
    Stoller RG; Hande KR; Jacobs SA; Rosenberg SA; Chabner BA
    N Engl J Med; 1977 Sep; 297(12):630-4. PubMed ID: 302412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum profiles and safety of intermediate-dose (500-1,000 mg) methotrexate following IV and IM administration.
    Colls BM; Robson RA; Robinson BA; Tisch GW
    Cancer Chemother Pharmacol; 1983; 11(3):188-90. PubMed ID: 6640826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of route of administration and effusions on methotrexate pharmacokinetics.
    Wan SH; Huffman DH; Azarnoff DL; Stephens R; Hoogstraten B
    Cancer Res; 1974 Dec; 34(12):3487-91. PubMed ID: 4429965
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of serum concentrations of methotrexate after various routes of administration.
    Freeman-Narrod M; Gerstley BJ; Engstrom PF; Bornstein RS
    Cancer; 1975 Nov; 36(5):1619-24. PubMed ID: 1192354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of the distribution of methotrexate in human tissues and tumors.
    Anderson LL; Collins GJ; Ojima Y; Sullivan RD
    Cancer Res; 1970 May; 30(5):1344-8. PubMed ID: 5426936
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacokinetics of urinary excretion of methotrexate (MTX) in patients with malignant tumors].
    Skibińska L
    Pol Tyg Lek; 1992 Jun 15-29; 47(24-26):545-8. PubMed ID: 1480527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumours.
    Christophidis N; Vajda FJ; Lucas I; Moon WJ; Louis WJ
    Br Med J; 1979 Feb; 1(6159):298-300. PubMed ID: 421088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer treatment by methotrexate: rational use following pharmacokinetic study.
    Lokiec F; Clavel B; Meeus L; Turpin F; Goupil A; Tubiana-Hulin M; Gest J
    Int J Nucl Med Biol; 1984; 11(1):107-8. PubMed ID: 6735604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis.
    Ortiz-Alvarez O; Morishita K; Avery G; Green J; Petty RE; Tucker LB; Malleson PN; Cabral DA
    J Rheumatol; 2004 Dec; 31(12):2501-6. PubMed ID: 15570658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness of the radioimmunologic method in the clinical monitoring of high-dosage methotrexate cancer therapy].
    Raimondo S; Bombardieri E; Cozzi A; Buraggi GL
    Radiol Med; 1980 Nov; 66(11):850-1. PubMed ID: 7221058
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of timing of a single injection on the toxicity of methotrexate in the rat.
    English J; Aherne GW; Marks V
    Cancer Chemother Pharmacol; 1982; 9(2):114-7. PubMed ID: 7172405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.
    Erttmann R; Bielack S; Landbeck G
    Cancer Chemother Pharmacol; 1985; 15(2):101-4. PubMed ID: 3874719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The variability of individual tolerance to methotrexate in cancer patients.
    Hansen HH; Selawry OS; Holland JF; McCall CB
    Br J Cancer; 1971 Jun; 25(2):298-305. PubMed ID: 4256007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: Altered plasma pharmacokinetics of methotrexate administered intrathecally.
    Jacobs SA; Bleyer WA; Chabner BA; Johns DG
    Lancet; 1975 Feb; 1(7904):465-6. PubMed ID: 48664
    [No Abstract]   [Full Text] [Related]  

  • 19. Tissue distribution of folate antagonists.
    Oliverio VT; Zaharko DS
    Ann N Y Acad Sci; 1971 Nov; 186():387-99. PubMed ID: 4943809
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy.
    Lankelma J; van der Klein E; Ramaekers F
    Cancer Lett; 1980 Apr; 9(2):133-42. PubMed ID: 7189691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.